Skip to main content

CRISPR technologies frequently asked questions

CRISPR tools

Can I contribute or access research tools that contain CRISPR-CAS9 technology?

Contribute: If you have developed modified cell lines using CRISPR-Cas9 please get in touch.

Access: Cancer Research Technology Limited (trading research tools as CancerTools.org) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed below.  This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license.

ERS Genomics Ltd holds an exclusive worldwide license from Dr. Emmanuelle Charpentier to the foundational intellectual property covering CRISPR-Cas9 for all applications other than use as a human therapeutic. The patent rights belonging to ERS Genomics Ltd are listed below. These patent applications have broad and dominant claims covering CRISPR-Cas9 compositions and methods of genome editing in any organism.

Click to view ERS Genomics Ltd Granted Patents

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.